Clinical Trial Update: Study of SBP-101 in Pancreatic Cancer [Phase 1]

View source ↗

Summary

A Phase 1 study of SBP-101 in pancreatic cancer (ductal adenocarcinoma of the pancreas) conducted by Panbela Therapeutics has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer
• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• SBP-101 (SBP-101 (polyamine analog))

Snippet

Sponsor: Panbela Therapeutics, Inc. | Conditions: Pancreatic Cancer, Ductal Adenocarcinoma of the Pancreas | Phase 1 | Status: COMPLETED